Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000579

Drug Information
NameMotesanib diphosphate
SynonymsS1032_Selleck; Motesanib diphosphate; Motesanib diphosphate [USAN]; D08947; 857876-30-3; Motesanib diphosphate (USAN); UNII-T6Q3060U91; AMG-706. Motesanib Diphosphate; EC-000.2343
CompanyTakeda
IndicationProgressive non-small cell lung cancer
[ICD9: 162   ICD10: C33, C34]
Phase I    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C22H23N5O.2H3O4P/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)
17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15;2*1-5(2,3)4/h3-12,26H,
13-14H2,1-2H3,(H,24,25)(H,27,28);2*(H3,1,2,3,4)
InChIKeyONDPWWDPQDCQNJ-UHFFFAOYSA-N
Canonical SMILESCC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C.OP(=O)(O)O.OP(=O)
(O)O    
CAS NumberCAS 850649-62-6
PubChem Compound IDCID 16097729.
PubChem Substance IDSID 22395889.
ClinicalTrials.govNCT00324597;
TargetC-kitInhibitor[1][2]
C-kitMultitarget[1][2]
Platelet-derived growth factor receptorInhibitor[1][2]
Platelet-derived growth factor receptorMultitarget[1][2]
VEGFR2Inhibitor[1][2]
VEGFR2Multitarget[1][2]
Ref 1Takeda. Product Development Pipeline. July 31 2009. To Reference
Ref 2Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009 Aug 10;27(23):3794-801. Epub 2009 Jun 29. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543